PBAC's latest decision on Follitropin alfa + lutropin alfa; lutropin alfa: Recommended (2016). Considered for Stimulation of follicular development in assisted reproductive technology (IVF) under the Section 100 program.
PBAC outcome
Recommended
Restricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2016
Submissions
1
2016 → 2016
Eligible population
Patients undergoing ovarian stimulation for assisted reproductive technology (IVF) under the Section 100 program.
Therapy area
Women's health
Line of therapy
Not applicable
Evidence base
Meta-analysis
Key trials
Lehert et al (2014), Study 2008, Burgues et al (2011)
Economic model
Not modelled
ICER note
Not modelled — minor submission requesting increase to maximum quantities only; no economic evaluation conducted.